Autonomix Medical (NASDAQ:AMIX) Now Covered by Analysts at Maxim Group

Maxim Group assumed coverage on shares of Autonomix Medical (NASDAQ:AMIX) in a research report released on Tuesday morning,Benzinga reports. The brokerage issued a buy rating and a $5.00 target price on the stock.

Autonomix Medical Stock Performance

Shares of Autonomix Medical stock opened at $2.53 on Tuesday. Autonomix Medical has a 52-week low of $1.52 and a 52-week high of $70.10. The firm has a 50-day moving average of $2.06 and a 200-day moving average of $4.54. The stock has a market cap of $6.23 million, a PE ratio of -0.20 and a beta of -3.08.

Autonomix Medical (NASDAQ:AMIX) last announced its earnings results on Thursday, February 13th. The company reported ($1.46) EPS for the quarter. Equities research analysts predict that Autonomix Medical will post -10 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Autonomix Medical

An institutional investor recently bought a new position in Autonomix Medical stock. Citadel Advisors LLC purchased a new position in shares of Autonomix Medical, Inc. (NASDAQ:AMIX) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 47,884 shares of the company’s stock, valued at approximately $180,000. Citadel Advisors LLC owned 4.16% of Autonomix Medical at the end of the most recent quarter. 10.78% of the stock is owned by institutional investors.

Autonomix Medical Company Profile

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals.